CME/CE Podcast: Considering a Non-Steroidal MRA for CKD...Here’s What You Need to Know! Part 1 - Recognizing and Reducing Hyperkalemia Risk in CKD Patients
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Considering a Non-Steroidal MRA for CKD...Here's What You Need to Know! Part 1 - Recognizing and Reducing Hyperkalemia Risk in CKD Patients
Featuring George Bakris, MD as faculty, moderated by Robert D. Toto, MD.
Summary
In this 3-part educational podcast series moderated by Dr. Robert D. Toto, faculty discuss the management of chronic kidney disease using a non-steroidal MRA and what you really need to know now. In part 1, Dr. George Bakris and Dr. Robert D. Toto discuss the clinical risks of hyperkalemia in chronic kidney disease and ways to reduce these risks.
Chronic kidney disease (CKD) is associated with increased cardiovascular risk, and mortality in CKD patients is often due to cardiovascular disease (CVD). Inflammation, fibrosis, and the mineralocorticoid receptor (MR) play important roles in CKD progression and CVD risk, while MR antagonists (MRAs) reduce CVD risk and CKD progression. Older steroidal MRAs have several limitations, including causing hyperkalemia, which is a potentially serious electrolyte abnormality that is already more common among CKD patients. This podcast series will provide clinicians with additional information on available MRAs and how to use them in the care of patients with CKD.
This podcast was recorded and is being used with the permission of the presenters.
Learning Objectives
Upon completion of this activity, learners should be able to:
- Identify strategies to reduce the risk of hyperkalemia in patients with CKD
This activity is accredited for CME/CE Credit.
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Considering a Non-Steroidal MRA for CKD...Here's What You Need to Know! Part 1 - Recognizing and Reducing Hyperkalemia Risk in CKD Patients
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).
This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
